Hepatology

Medical Oncology

Questions discussed in this category

Would you recommend radiation or chemoradiation in a patient with cholangiocarcinoma s/p surgery and adjuvant treatment with single hepatic metastasis 3 years later?

Patient with extrahepatic cholangiocarcinoma s/p Whipple in 2021 with negative margins and no positive nodes followed by adjuvant chemo with subsequen...

1 Answer available

Would you ever consider using durvalumab/tremelimumab in second line after progression on atezolizumab and bevacizumab in advanced HCC?

3 Answers available

How do you manage oxaliplatin-induced splenomegaly?

1 Answer available

What is your standard diagnostic workup to confirm GVHD in a patient post-BMT with skin rash and jaundice?

2 Answers available

How do you approach restarting immunotherapy in a patient with metastatic melanoma who previously developed immune-mediated hepatitis (Grade 3), with liver enzymes now back to baseline levels?

Given the improvement in liver function, what factors should be considered before reinitiating immunotherapy?"

4 Answers available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Mar 19

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.

Hepatology (Baltimore, Md.), 2023 May 22

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.

Hepatology research : the official journal of the Japan Society of Hepatology, 2025 Jan 15

Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinoma.

Investigational new drugs, 2024 Aug 30

Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma.

Cancer chemotherapy and pharmacology, 2019 Aug 23

Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-05-20

Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.

Hepatology

Medical Oncology

Questions discussed in this category

Papers discussed in this category

Related Topics in Hepatology